Questcor (Nasdaq: QCOR) is a smaller player in the biotech space that has garnered a lot of attention on Fool.com. In this video, Motley Fool health-care bureau chief Brenton Flynn talks about his recent look through the SEC filings of this company, and some of the less-reported information that he found. One play the company is making: a move toward pushing for another indication, rheumatology, which the company is already moving a sales force behind.
Questcor is one of the most debated names in all of biotech. Its premium-priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand-new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.